Anti-Agitation Drug Comes Up Short in Phase 3
Negative findings for AVP-786 belie positive findings from a separate Phase 3 trial announced earlier this year.
ALL NEWS
54 RESULTS
Sort By:
- Most Recent
- Most Commented
TOM1: A Check on Runaway Inflammation in Alzheimer’s?
The protein helps internalize neuronal interleukin receptors. It also promotes microglial phagocytosis. Does its absence worsen neuroinflammation and Aβ burden?
Tau Natively Unstructured? Not Always, New Study Says
Using chemical cross-linkers to map contacts among amino acids, structural biologists predict that soluble tau is, in fact, a compact globule containing β-sheets poised to snap into a pathological formation.
New Funding for Tauopathies
A $400,000 prize is to be awarded as part of the new Rainwater program, and $63 million of NIH money will support a research consortium on frontotemporal dementias.
Human Microglia Eat Synapses, More So in Alzheimer’s
Evidence from postmortem human brains and cultured human microglia suggests the immune cells make a meal out of synapses, especially near plaques.
Dipeptide Repeat Proteins Don’t Directly Block Nuclear Transport
New data suggest that while peptides translated from an expansion in the C9ORF72 gene are toxic, they don’t directly interfere with nucleocytoplasmic transport.
Minocycline Does Not Work in Mild Alzheimer’s Disease
Based on preclinical data, researchers gave this antibiotic a shot in a two-year clinical trial. It did nothing to slow cognitive decline.
Society for Neuroscience Annual Meeting 2019
Not Just Blood Pressure—Dietary Salt Linked to Tau Phosphorylation Time to Try Again: Gene-Based Therapy for Neurodegeneration Gene Therapies Enter Trials for Many Brain Pathologies—What about AD? Organized around 10 major themes, this year’s annual meeti
Can Induced Neurons Identify Early Signs of Neurodegeneration?
In patient-derived neurons, tau mutations scupper lysosomes and SORLA shunts APP through different types of endosomes.
Current Filters
- Date Range : Sep 2019 to Dec 2019 x